Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Lymphoma, Large B-Cell, Diffuse 29Lymphoma, Non-Hodgkin 8Lymphoma, B-Cell 7Lymphoma 5Lymphoma, Follicular 4Recurrence 3Lymphoma, B-Cell, Marginal Zone 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Dendritic Cell Sarcoma, Interdigitating 2Burkitt Lymphoma 2Neoplasms 1Lymphoma, Mantle-Cell 1Leukemia, Hairy Cell 1Hematologic Neoplasms 1

Interventions

venetoclax 69Cyclophosphamide 53ibrutinib 45obinutuzumab 43acalabrutinib 43Rituximab 40fludarabine 37fludarabine phosphate 30Specimen Handling 29pirtobrutinib 26Biopsy 24zanubrutinib 23Whole-Body Irradiation 16Bendamustine Hydrochloride 15Magnetic Resonance Spectroscopy 14Mycophenolic Acid 13Lenalidomide 11Peripheral Blood Stem Cell Transplantation 9Sirolimus 8idelalisib 7Tacrolimus 7CT-P10 7ARQ531 7tafasitamab 6Prednisone 6Busulfan 6pembrolizumab 5Stem Cell Transplantation 5Melphalan 5Interleukin-2 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Lymphocytic, Chronic, B-Cell × polatuzumab vedotin × 1 year × Clear all
NCT06043674 2026-01-07

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

Dana-Farber Cancer Institute

Phase 2 Recruiting
70 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04679012 2025-10-07

Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

Weill Medical College of Cornell University

Phase 2 Recruiting
20 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡